 | | | | - Compared with industrial mean, the Earning Rate comparison Volatility was negative | | - Most of related stocks also decline. Medical Supplies industry -1.22% | | - Target price KRW 65,000, has 57% disparate to increase compared with stock price. | | - Institutions and Foreigners sell, Individuals buy | | - Turnover Rate and Price Range both proper | | - The main shareholding group is Individuals |
|
|
On Oct. 24, Ilyang Pharmaceutical (007570) declined 2.71% to 41,350 won (US$ 36.49). It had declined 16.21% through the past month. Standard deviation, which indicates volatility of stock, records 2.5% over the same period over one month.
Compared with its close competitors within the same industry, KOSPI, even though the monthly earnings rate of Ilyang Pharmaceutical recorded negative, its volatility for 1 month was proper. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -6.4%. In spite of stock price decline, the return-on-risk remained around the average of its peer group. However, compared with the KOSPI industry, the return-on-risk is below the industrial mean, -0.5, and thus it is hard to say that the industrial comparison performance was positive.
| Close Competitors | Earning rate (%) | STD (1Mo) | Return on
Risk (1Mo) | | 1 Mo | 3 Mo | 6 Mo | | HANALL BIOPHARMA(009420) | -30.0% | -39.9% | -12.4% | 3.2% | -9.3 | | DAEWOONG PHARMA(069620) | -7.3% | -25.7% | -21.8% | 2.6% | -2.8 | | ILYANG PHARM(007570) | -16.2% | -20.5% | -16.1% | 2.5% | -6.4 | | DONG-A ST(170900) | -17.4% | -24.0% | -36.1% | 2.2% | -7.9 | | BORYUNG PHARM(003850) | -7.8% | -6.8% | 6.4% | 1.8% | -4.3 | | | | Medical Supplies | -17.0% | -16.8% | -21.7% | 1.7% | -10.0 | | KOSPI | -0.3% | -0.6% | 1.3% | 0.6% | -0.5 |
|
ILYANG PHARM(007570): 2Q(Apr ~ June) of 2016 Earnings (reported at July 26. 2016)
| | Revenue | Operating Income | Net Income | | 2Q of 2016 | 616.0 T | 42.1 T | 27.0 T | | Previous Quarter | 5.5% increase | 42.7% decline | 34.2% decline | | YoY | 43.8% increase | 142.1% increase | 233.8% increase |
|
Financial structure Overview
| Compared with 4 close competitors with similar market capitalization within its industry, ILYANG PHARM's P/B ratio, a financial ratio of a company's book value, and its P/E ratio, a price-paid ratio of annual net income, are both at a relatively higher level. |
P/E ratio and P/B ratio
| Close Compatitors | ROE | PER | PBR | Basic Date | | ILYANG PHARM(007570) | 5.4 | 69.7 | 3.8 | June 2016 | | DAEWOONG PHARMA(069620) | 3.5 | 42.3 | 1.5 | June 2016 | | HANALL BIOPHARMA(009420) | -4.1 | - | 7.1 | June 2016 | | DONG-A ST(170900) | 5.0 | 28.7 | 1.4 | June 2016 | | BORYUNG PHARM(003850) | 10.4 | 24.3 | 2.5 | June 2016 |
Institutions and Foreigners sell, Individuals buy
While institutions have been selling Ilyang Pharmaceutical during the past 7 trading days, foreigners have been buying during the past 2 trading days. As a shareholding sum by investor group for the past 4 weeks, foreigners have sold 74,034 shares and institutions have sold 72,817 shares with a selling trend. However, during the same period, individuals have bought 146,851 shares with an increasing position.
| Cumulated shareholdings per investor group (1Mo) | | Total shareholdings per investor group |  | |  |
| * Other Investor groups, included as "other corporations", are considered as "Individuals". |
By HeRo (hero@heraldcorp.com) This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp. |
![[Weekender] Korean psyche untangled: Musok](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=645&simg=/content/image/2024/05/02/20240502050841_0.jpg&u=)
![[Eye Interview] 'If you live to 100, you might as well be happy,' says 88-year-old bestselling essayist](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=645&simg=/content/image/2024/05/03/20240503050674_0.jpg&u=)
